Rosh Pina, Israel--(Newsfile Corp. - September 16, 2025) - IR-MED Inc. (OTCQB: IRME) ("IR-MED" or the "Company"), a developer of non-invasive artificial intelligence (AI)-powered spectrographic technology to address critical healthcare challenges, today published an investor update. Please note that based on the Company’s current expected level of operating expenditures, the Company’s cash resources as of June 30, 2025 , the Company’s ability to undertake the operational and strategic actions described in this update is contingent upon securing additional funding. The IIA grant funding will support clinical advancement of DiaSafe™, an AI-powered diagnostic device for diabetic foot ulcers. The first in human clinical study is planned to commence soon in a leading medical center in Northern Israel. DiaSafe™ with its complementary AI-driven solutions positions IR-MED to address additional large wound care markets among high-risk diabetic patients.